Company Quick10K Filing
Lixte Biotechnology Holdings
10-Q 2020-03-31 Filed 2020-05-11
10-K 2019-12-31 Filed 2020-03-25
10-Q 2019-09-30 Filed 2019-11-08
10-Q 2019-06-30 Filed 2019-08-06
10-Q 2019-03-31 Filed 2019-05-09
10-K 2018-12-31 Filed 2019-03-25
10-Q 2018-09-30 Filed 2018-11-08
10-Q 2018-06-30 Filed 2018-08-02
10-Q 2018-03-31 Filed 2018-04-27
10-K 2017-12-31 Filed 2018-03-23
10-Q 2017-09-30 Filed 2017-11-09
10-Q 2017-06-30 Filed 2017-08-04
10-Q 2017-03-31 Filed 2017-05-10
10-K 2016-12-31 Filed 2017-03-29
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-10
10-Q 2016-03-31 Filed 2016-05-06
10-K 2015-12-31 Filed 2016-03-28
10-Q 2015-09-30 Filed 2015-11-10
10-Q 2015-06-30 Filed 2015-08-07
10-Q 2015-03-31 Filed 2015-05-13
10-K 2014-12-31 Filed 2015-03-27
10-Q 2014-09-30 Filed 2014-11-12
10-Q 2014-06-30 Filed 2014-08-08
10-Q 2014-03-31 Filed 2014-05-09
10-K 2013-12-31 Filed 2014-03-21
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-05
10-Q 2013-03-31 Filed 2013-05-09
10-K 2012-12-31 Filed 2013-03-15
10-Q 2012-09-30 Filed 2012-11-13
10-Q 2012-06-30 Filed 2012-08-10
10-Q 2012-03-31 Filed 2012-05-10
10-K 2011-12-31 Filed 2012-03-29
10-Q 2011-09-30 Filed 2011-11-10
10-Q 2011-06-30 Filed 2011-08-12
10-Q 2011-03-31 Filed 2011-05-09
10-K 2010-12-31 Filed 2011-03-28
10-Q 2010-09-30 Filed 2010-11-04
10-Q 2010-06-30 Filed 2010-08-10
10-Q 2010-03-31 Filed 2010-05-04
10-K 2009-12-31 Filed 2010-03-29
8-K 2019-07-31 Enter Agreement, Other Events, Exhibits
8-K 2018-11-30 Sale of Shares, Exhibits
8-K 2018-11-05 Other Events, Exhibits
8-K 2018-08-20 Enter Agreement, Other Events, Exhibits
8-K 2018-08-04 Officers, Other Events, Exhibits

Lixte Biotechnology Holdings Financials

LIXT Metrics, Comps, Filings

Quarterly | Annual

Business

Lixte Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the “Company”), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

The Company's activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, and is dependent on periodic infusions of equity capital to fund its operating requirements.

The Company's primary focus is developing new treatments for human cancers for which better therapies are urgently needed. The scope of potential applications of the Company's products has expanded to other common non-malignant diseases, including vascular diseases (heart attacks and stroke, diabetes, genetic diseases, such as Gaucher's disease), and recently to depression and potentially post-traumatic stress syndrome. This has occurred because the targets selected by the Company have multiple functions in the cell, which, when altered, result in different disorders that may benefit by treatment from the Company's products.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Lexaria Bioscience (LXRP) 70,079 188% -16.1 -124% 3,457 132 97 183 -4,270 -4,216 68,083
NaturalShrimp (SHMP) 56,698 -7.8 -253% 2,967 5,223 0 0 -7,504 -7,277 56,414
Greenbox Pos (GRBX) 56,573 83% -10.4 -738% 750 919 588 489 -5,535 -5,452 56,573
Highlands Bankshares (HBKA) 55,852 5.1 0% 575,274 513,906 0 0 2,477 6,475 33,031
CTD Holdings (CTDH) 55,713 92% -10.4 -84% 5,862 2,379 780 717 -4,898 -4,898 50,719
IEH Corporation (IEHC) 55,524 30% 6.8 14% 29,026 4,472 27,884 8,433 4,193 7,167 48,961
Imageware Systems (IWSY) 54,453 81% -5.7 -75% 11,759 8,663 2,528 2,046 -8,825 -8,770 50,090
Cyberfort Software (CYBF) 54,167 -117.5 0 788 0 0 -422 -461 54,167
Weed (BUDZ) 54,162 -2.2 -969% 2,539 760 0 0 -24,599 -24,471 54,149
Lixte Biotechnology Holdings (LIXT) 53,637 -23.9 -69% 3,066 309 0 0 -2,118 -2,118 50,660
Discovery Energy (DENR) 53,179 6.3 200% 3,159 5,564 0 0 6,325 8,434 53,056
School Specialty (SCOO) 53,419 33% -10.8 -15% 354,249 300,481 649,666 214,195 -51,604 -22,825 246,625
Victory Oilfield Tech (VYEY) 53,272 46% -2.1 -166% 19,052 3,203 399 184 -31,533 -31,259 64,811
Applied Energetics (AERG) 53,091 -14.0 -128% 3,130 5,690 0 0 -4,007 -3,920 54,942
Uber (UBER) 51,975,266 49% -3.1 -50% 31,761,000 16,578,000 14,147,000 6,939,000 -15,919,000 -15,045,000 46,809,266
Ipsidy (IDTY) 51,813 74% -8.8 -42% 16,101 4,284 1,938 1,429 -6,797 -5,947 52,051
Skkynet Cloud Systems (SKKY) 51,488 99% -106.3 -52% 924 312 1,039 1,028 -478 -478 50,787
Achison (ACHI) 51,426 0% -1,789.5 -10% 272 0 36 0 -26 -29 51,284
Pacific Health Care Organization (PFHO) 51,264 0% 32.5 9% 10,142 1,145 5,437 0 915 1,328 43,163
Wave Sync (WAYS) 50,467 1% -8.7 -74,373% 8 1,415 156 2 -5,791 -5,787 50,466

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash3413014692,1771,8811,6551,3751,075791475115479441401272182599966702008712,0321,5901,3068085363744,2733,8943,5642,976
Accounts Receivable
Inventory
PP&E
Assets1,4211,0014302022,2551,9621,7531,4811,1458745581881,3029965391,6821,5251,0275981,2251,3799344339212,0651,6511,3688555834454,3373,9553,6193,066
Accounts Payable
Long-Term Debt
Liabilities337362351467351246261270266294322284327402273254198222286193140196219254242256373239338459211245223309
Stockholders' Equity1,08463879-2661,9031,7151,4921,211879580236-969755942661,4281,3278053121,0321,2397382156661,8231,395995616244-144,1263,7103,3962,756
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue0000000000000000002000000000000
Cost of Revenue66666
Gross Profit-6
R&D224364485274217394128166249220245163336309310506287624675264317477243303137206104264134880571
SG&A124135185318183444148168120931145536411923582472141551391522381702733183032583293543311,031390548522
Tax00000000000000000000000000000000
Net Income-348-699-670-592-734-1,978-276-334-369-313-359-929-741-501-595-958-501-780-614-417-555-647-516-621-266-462-433-379-371-1,034-429-610-1,079
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-404-566-249-435-296-226-281-299-284-316-360-294-338-644-539-521-509-612-326-402-480-470-329-338-460-284-498-272-165-379-330-588
Cash Investing50045027075000000-1,188300680-1,103193600420-767-1831,05400000
Cash Financing00332,46800000001,412001,737315001,167581001,0001,500180003